Clinical Trials Directory

Trials / Terminated

TerminatedNCT01895582

Performance of IGRAs for TB Infection Diagnosis in Elderly

Mycobacterium Tuberculosis Infection Diagnosis in Patients Above 75 Years Old/ Performance of Interferon Gamma Releasing Assays (IGRA)

Status
Terminated
Phase
Study type
Observational
Enrollment
160 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
75 Years
Healthy volunteers
Not accepted

Summary

Background: Diagnosis and screening for latent tuberculosis in old patients is of special interest in regards of the morbidity-mortality of this disease in that context. TB-infection diagnosis based on immunological memory detection can be impaired with age. New blood tests (QFTB-G and T-SPOT.TB) specific for MTB infection have not been evaluated in those old patients.The primary endpoint of this study is the evaluation of the IGRAS for active TB diagnosis in patients above 75 years old.

Detailed description

In vitro Interferon Gamma releasing Assay (IGRA) are recommended for LTBI screening as or instead of TST, but there accuracy in those old patients are not known: as immune responses are impaired in elderly and some of them have already met M tuberculosis before active antibiotherapy exists.The aim of this study is to evaluate characteristics of the two commercials tests IGRA T-spot-TB® and Quantiferon-TB-gold- in tube® and TST in old patients with or without active Tuberculosis. Principal outcome: \- 3 tests performance for active TB diagnosis in patients older than 75 years-old Secondary outcomes : * concordance between IGRAs. * non-concordant results analysis * concordance of IGRAs results with time of TB-infection * biobank Methodology :Diagnostic test performance study

Conditions

Interventions

TypeNameDescription
OTHERBlood samples4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml) 1 blood dry tube (5ml)

Timeline

Start date
2013-07-17
Primary completion
2019-03-17
Completion
2019-03-17
First posted
2013-07-10
Last updated
2021-05-28

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01895582. Inclusion in this directory is not an endorsement.